Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Solid Biosciences’ 250-page 10-K can feel like decoding a genetic sequence. Trial protocols, vector design risks, and cash-burn tables are buried in dense language that makes it hard to answer one basic question: Is the next Duchenne milestone funded and on track?
That’s why Stock Titan pairs every document with AI-powered summaries that turn biotech jargon into clear insights. Need the Solid Biosciences quarterly earnings report 10-Q filing broken down line-by-line? Our engine highlights R&D spend shifts and runway projections in seconds. Curious about Solid Biosciences insider trading Form 4 transactions or the latest Solid Biosciences 8-K material events explained? Real-time EDGAR feeds alert you the moment they post, while plain-language notes flag anything that could move the share price.
Explore every form without searching page after page:
- 10-K & 10-Q – Cash runway and pipeline data, with the Solid Biosciences annual report 10-K simplified for quick reading.
- 8-K – Trial pauses, FDA feedback, partnerships, all filed under “Solid Biosciences earnings report filing analysis”.
- Form 4 – Track Solid Biosciences Form 4 insider transactions real-time and spot Solid Biosciences executive stock transactions Form 4 patterns.
- Proxy (DEF 14A) – See the full Solid Biosciences proxy statement executive compensation without hunting through attachments.
Form 4 highlights: On 07/06/2025, Solid Biosciences Inc. (SLDB) director Ian F. Smith acquired 4,573 common shares through the mandatory conversion (Code M) of previously granted restricted stock units (RSUs). The RSUs, issued on 01/06/2025, vest in four equal quarterly tranches and convert to common stock on a 1-for-1 basis. Following the transaction, Smith now directly owns 122,119 common shares and retains 9,146 unvested RSUs. The RSUs will accelerate in full if the Executive Chair Agreement terminates early or upon a change in control of the company. No shares were sold, suggesting continued insider exposure to SLDB’s equity. The filing was signed on 07/08/2025.
Solid Biosciences (NASDAQ:SLDB) filed a routine Form 4 disclosing that director Georgia Keresty received a stock-option grant covering 77,500 shares on 06/12/2025 at an exercise price of $4.58 per share.
The option vests in full on the earlier of the one-year anniversary of the grant or immediately prior to the next annual shareholder meeting, and accelerates upon certain change-in-control events. It expires on 06/12/2035. No open-market purchases or sales of common stock were reported, and Keresty’s beneficial ownership now reflects only the newly granted option, held directly.
FAQ
What is the current stock price of Solid Bioscience (SLDB)?
What is the market cap of Solid Bioscience (SLDB)?
What is the primary focus of Solid Biosciences?
How does Solid Biosciences approach its treatment development?
What sets Solid Biosciences apart from other biotech companies?
In which disease areas does Solid Biosciences operate?
What type of therapies does the company develop?
How does Solid Biosciences ensure scientific credibility?
